title: Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
abstract: 277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients.
authors.affiliation: Abt. Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und Dermatologie Med. Hochschule Hannover, FRG.
authors.forename: D
authors.initials: D
authors.lastname: Peest
authors.forename: H
authors.initials: H
authors.lastname: Deicher
authors.forename: R
authors.initials: R
authors.lastname: Coldewey
authors.forename: R
authors.initials: R
authors.lastname: Leo
authors.forename: R
authors.initials: R
authors.lastname: Bartl
authors.forename: H
authors.initials: H
authors.lastname: Bartels
authors.forename: H J
authors.initials: HJ
authors.lastname: Braun
authors.forename: I M
authors.initials: IM
authors.lastname: von Broen
authors.forename: J T
authors.initials: JT
authors.lastname: Fischer
authors.forename: M
authors.initials: M
authors.lastname: Gramatzki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone